

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
1 February 2001 (01.02.2001)

PCT

(10) International Publication Number
WO 01/07417 A1

- (51) International Patent Classification⁷: **C07D 239/16, A61K 31/505, C07D 239/42**
- (21) International Application Number: **PCT/EP00/06504**
- (22) International Filing Date: **8 July 2000 (08.07.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
99114372.8 21 July 1999 (21.07.1999) EP
- (71) Applicant (for all designated States except US): **AVENTIS PHARMA DEUTSCHLAND GMBH [DE/DE];**
Brüningstrasse 50, 65929 Frankfurt am Main (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BREIPOHL, Gerhard [DE/DE];** Geisenheimer Strasse 95, 60529 Frankfurt am Main (DE). **PEYMAN, Anuschirwan [DE/DE];** Zeilsheimer Strasse 46, 65779 Kelkheim (DE). **WOLLMANN, Theodor [DE/DE];** Im Heideck 11, 65795 Hattersheim (DE).
- (74) Agent: **VIEILLEFOSSE, Jean, Claude;** Hoechst Marion Roussel, 102, route de Noisy, F-93235 Romainville Cedex (FR).
- (81) Designated States (national): AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **1,4,5,6-TETRAHYDOPYRIMIDINE DERIVATIVE AS A VITRONECTIN INHIBITOR**



(57) Abstract: The present invention relates to ethyl (2S)-2-(naphthalene-1-sulfonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionate hemifumarate of formula (I), and to a process for its preparation comprising reacting 4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoic acid or a derivative thereof and ethyl (2S)-3-amino-2-(naphthalene-1-sulfonylamino)propionate. The compound of formula (I) is a valuable pharmaceutical which can be used, for example, in the treatment or prophylaxis of diseases which can be influenced by inhibiting the vitronectin receptor, in particular of bone diseases such as osteoporosis. The invention furthermore relates to chemical intermediates useful for the preparation of the compound of formula (I).

WO 01/07417 A1